ClinicalTrials.gg
Active, not recruitingNCT05491980Updated Sep 3, 2026

Florida Cerebrovascular Disease Biorepository and Genomics Center

An observational study in Cerebrovascular Disease, Ischemic Stroke and Transient Ischemic Attack, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Mayo Clinic · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
72
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to create a state-wide biorepository and resource center for cerebrovascular diseases in Florida, which will include collecting medical history information and blood from subjects affected by cerebrovascular disease. The information and blood samples collected may be used in future research for the study of cerebrovascular disease and to learn about, prevent or treat other health problems.

02

Conditions studied

  • Cerebrovascular Disease
  • Ischemic Stroke
  • Transient Ischemic Attack
  • Intracerebral Hemorrhage
  • Aneurysmal Subarachnoid Hemorrhage
  • Vascular Dementia
  • Anoxic Brain Injury
  • Unruptured Intracranial Aneurysm
  • Carotid Artery Stenosis Symptomatic
  • Asymptomatic Carotid Artery Stenosis
  • Non-Aneurysmal Perimesencephalic Subarachnoid Haemorrhage
  • Cerebral Venous Thrombosis
  • Moyamoya Disease
  • Fibromuscular Dysplasia
  • Subarachnoid Hemorrhage
  • Leukoaraiosis
  • Arteriovenous Fistula
  • Reversible Cerebral Vasoconstriction Syndrome
  • CADASIL
03

In context

Cerebrovascular Disorders

449 studies on the registry are indexed under Cerebrovascular Disorders; 127 are open to participants now.

This study's enrollment of 72 is below the median of 450 across 145 observational studies indexed under Cerebrovascular Disorders.

Browse Cerebrovascular Disorders studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects identified with a history of cerebrovascular disease will be recruited from both the in-patient and outpatient services at Mayo Clinic Florida.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Affected subjects with diverse cerebrovascular conditions, including, but not limited to, ischemic stroke, (TIA), intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (aSAH), vascular dementia (VAD), anoxic brain injury, unruptured intracranial aneurysm (UIA), cavernous malformation, arteriovenous malformations (AVM), carotid and vertebral arterial dissections, symptomatic and asymptomatic cervical carotid artery atherosclerotic stenosis, non-aneurysmal perimesencephalic subarachnoid hemorrhage (naSAH), cerebral venous thrombosis (CVT), moyamoya disease, fibrosmuscular dysplasia (FMD), non-traumatic, angiography-negative subarachnoid hemorrhage, leukoaraiosis, arteriovenous fistula, reversible cerebral vasoconstriction syndrome (RCVS), and CADASIL.

Exclusion criteria

Exclusion Criteria:

  • All patients with the following known or suspected virulent microorganisms causing an active or latent infection will be excluded from the study:
  • (HIV);
  • Any viral hepatitis;
  • West Nile virus (WNV);
  • Influenza virus;
  • Tuberculosis (TB);
  • Any bacteremia;
  • Any fungemia;
  • Any prionopathy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
72 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Stroke or TIA at 12 months

    Number of participants to experience new diagnosis of TIA or stroke.

    Time frame: 1 year

Secondary outcomes

  1. Modified Rankin Scale

    Measure of overall functional status

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Jun 2030, 94 months after the start.

Of 75 non-industry observational studies under Cerebrovascular Disorders, half reached primary completion within 103 months of starting (the median), counting those still running; a quarter within 59 and three quarters within 339. This study's planned 94 months is close to that.

Counting every sponsor, half of 79 studies reached it within 103 months; a quarter within 46 and three quarters within 339.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2022
First posted
Aug 8, 2022
StartActual
Aug 2, 2022
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05491980
Lead sponsor
Mayo Clinic
Responsible party
James F. Meschia (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Aug 8, 2022
Start date
Aug 2, 2022
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Sep 3, 2026

Study contacts

James Meschia, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion